Aktionsplan ABIVAX Société Anonyme
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
| EBITDA |
-0.0333 |
| EV/EBITDA |
-0.3297 |
| IPO date |
2023-10-20 |
| ISIN |
US00370M1036 |
| Industry |
Biotechnology |
| P/BV |
2.13 |
| P/S |
90.21 |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
eur |
| Выручка |
2.3E-5 |
| Сайт |
https://www.abivax.com
|
| Цена ао |
10.29 |
| Число акций ао |
0.04307 млрд |
| Preisänderung pro Tag: |
-5.54% (10.29) |
| Preisänderung pro Woche: |
-16.21% (11.6) |
| Preisänderung pro Monat: |
-21.3% (12.35) |
| Preisänderung über 3 Monate: |
-26.59% (13.24) |
| Preisänderung über sechs Monate: |
-36.84% (15.39) |
| Preisänderung seit Jahresbeginn: |
+7.4% (9.05) |
|
|
Unterschätzung
| Name |
Bedeutung |
Grad |
| P/S |
90.21 |
1 |
| P/BV |
2.13 |
7 |
| P/E |
0 |
0 |
| EV/EBITDA |
-1.68 |
0 |
| Gesamt: |
|
3.88 |
|
Effizienz
| Name |
Bedeutung |
Grad |
| ROA, % |
-45.17 |
0 |
| ROE, % |
-75.37 |
0 |
| Gesamt: |
|
0 |
|
|
|
Dividenden
| Name |
Bedeutung |
Grad |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| Gesamt: |
|
0 |
|
Pflicht
| Name |
Bedeutung |
Grad |
| Debt/EBITDA |
-0.4212 |
10 |
| Gesamt: |
|
9.6 |
|
Wachstumsimpuls
| Name |
Bedeutung |
Grad |
| Rentabilität Revenue, % |
19991.3 |
10 |
| Rentabilität Ebitda, % |
294.32 |
10 |
| Rentabilität EPS, % |
-50.72 |
0 |
| Gesamt: |
|
8 |
|
| Aufsicht |
Berufsbezeichnung |
Zahlung |
Geburtsjahr |
| Dr. Philippe Pouletty M.D., Ph.D. |
Founder & Director |
N/A |
1958 (66 Jahre) |
| Mr. Marc M. P. de Garidel M.B.A. |
CEO & Director |
858.61k |
1958 (66 Jahre) |
| Mr. Didier Blondel |
EVP, CFO & Board Secretary |
N/A |
1964 (60 Jahre) |
| Mr. Didier Scherrer Ph.D. |
Chief Scientific Officer |
N/A |
1970 (54 Jahr) |
| Mr. Patrick Malloy |
Senior Vice President of Investor Relations |
N/A |
|
| Ms. Ida Hatoum |
Chief People & Compliance Officer |
N/A |
1975 (49 Jahre) |
| Mr. Pierre Courteille M.B.A. |
Chief Business Officer |
N/A |
1969 (55 Jahre) |
| Mr. Michael Ferguson B.S., M.B.A. |
Chief Commercial Officer |
N/A |
1978 (46 Jahre) |
| Mr. Jerome Denis Ph.D. |
Executive Vice President of Process Development & Manufacturing |
|
|
| Ms. Ana Sharma M.P.H. |
VP & Global Head of Quality |
|
|
